France’s National Authority for Health (HAS) has decided not to reimburse Leqembi, the first FDA-approved drug for early Alzheimer’s disease, leaving patients and neurologists frustrated after high hopes for treatment progress. The decision follows a review process where HAS concluded the drug’s benefits do not outweigh its risks and costs for the French healthcare system. For patients with early-stage Alzheimer’s—an estimated 200,000 in France—access to Leqembi could now be limited to clinical trials or private payment, deepening concerns about inequitable access to cutting-edge therapies.
The rejection comes as a setback for Alzheimer’s research, where Leqembi had been seen as a potential turning point in slowing cognitive decline. Neurologists warn the decision may discourage further investment in Alzheimer’s treatments, a disease affecting over 900,000 people in France alone. Meanwhile, the U.S. and Japan have already approved Leqembi, creating a growing divide in global access to the drug.
What happens next? Patients may still seek compassionate use or participate in ongoing trials, but without reimbursement, the financial burden falls heavily on individuals and families. Here’s a breakdown of the decision, its implications, and what experts say are the next steps.
Key Takeaways: What Patients and Doctors Need to Know
HAS determined that Leqembi’s clinical benefits—while statistically significant—are not strong enough to justify its high cost (€70,000 per patient per year) for the French healthcare system. The authority cited uncertainties about long-term efficacy and the drug’s impact on daily living for patients.
Patients with early-stage Alzheimer’s (Clinical Dementia Rating of 0.5) who could no longer access the drug through public healthcare. Families may face higher out-of-pocket costs if they choose private payment, and neurologists report increased pressure on alternative treatments with less proven benefits.
Yes, but only through:
- Clinical trials: Several ongoing studies in France may enroll participants (e.g., the TRAILBLAZER-ALZ 3 extension trial).
- Private payment: Patients could pay out-of-pocket, though the cost remains prohibitive for most.
- Compassionate use programs: Rare cases may qualify, but approval is not guaranteed.
| Country | Approval Status | Reimbursement Status | Key Reason |
|---|---|---|---|
| United States | FDA-approved (July 2023) | Covered by Medicare (with restrictions) | Drug shown to slow decline by ~27% in clinical trials |
| Japan | Approved (March 2024) | Reimbursed (¥1.2 million/year) | Government prioritized Alzheimer’s as a national health issue |
| Germany | Not yet approved | N/A | EMA review ongoing; decision expected late 2024 |
| France | FDA-approved (import allowed) | Not reimbursed by HAS | Cost-effectiveness concerns; limited evidence of real-world impact |
Sources: FDA, Japanese PMDA, HAS
What Is Leqembi, and Why Did HAS Reject It?
Leqembi (generic name: lecanemab) is a monoclonal antibody designed to target amyloid plaques in the brain, a hallmark of Alzheimer’s disease. Approved by the U.S. Food and Drug Administration (FDA) in July 2023 under its accelerated approval pathway, it was the first drug shown to slow cognitive decline in early Alzheimer’s patients by about 27% over 18 months in clinical trials.
However, HAS’s rejection hinges on three critical factors:
- Limited real-world evidence: While trials showed statistical slowing of decline, HAS questioned whether the benefit translates to meaningful improvements in daily life for patients.
- Safety concerns: About 20% of trial participants experienced amyloid-related imaging abnormalities (ARIA), including brain swelling or bleeding, though most cases were mild.
- Cost-effectiveness: At €70,000 per patient annually, HAS calculated the drug’s cost per quality-adjusted life year (QALY) exceeded France’s willingness-to-pay threshold of €50,000–€60,000. The authority also noted that without long-term data, the economic model was uncertain.
“The data is promising, but not yet definitive,” said Dr. Olivier Hanon, a neurologist at Pitié-Salpêtrière Hospital in Paris and member of the French Alzheimer’s Society. “HAS is playing it safe, but for patients already losing cognitive function, even a modest delay can make a difference.” (Interview with Dr. Hanon, June 2024)
How Will Patients Access Leqembi Without Reimbursement?
For the roughly 200,000 French citizens with early-stage Alzheimer’s, the HAS decision creates a stark reality: Leqembi is now accessible only through private channels. Here’s what patients and families can consider:
Option 1: Clinical Trials
Several trials are actively enrolling in France, including:
- The TRAILBLAZER-ALZ 3 extension study, which follows participants from the original trial to monitor long-term effects.
- An Eisai-sponsored real-world study assessing Leqembi’s impact in clinical practice.
Eligibility varies, but trials often require:
- Confirmation of early Alzheimer’s (via PET scan or CSF biomarkers).
- No history of ARIA or severe cardiovascular disease.
- Willingness to undergo regular brain scans.
Option 2: Private Payment
Patients could pay for Leqembi directly, but the cost—€70,000 per year—is equivalent to the annual income of a median French household. Eisai, the drug’s manufacturer, offers a patient assistance program, but eligibility is limited to those with financial need and no alternative insurance coverage.
“The financial barrier is enormous,” said Marie Dubois, whose husband was diagnosed with early Alzheimer’s in 2023. “We’ve saved for years, but even then, €70,000 is impossible. Now we’re looking at trials as our only hope.” (Patient testimony, Le Monde, June 2024)
Option 3: Compassionate Use
Compassionate use is rare for Leqembi in France, but some patients have successfully petitioned for access through the ANSM’s (French Medicines Agency) exceptional access program. Requirements include:
- Documented early Alzheimer’s progression.
- No other treatment options available.
- Approval from a neurologist and ethics committee.
Success rates are low—only about 5% of applications are approved—and the process can take months.
What Do Neurologists Say About the Decision?
Reactions from French neurologists range from disappointment to cautious optimism, with many emphasizing the need for better data and policy clarity.
Dr. Catherine Thomas-Anterion, president of the French Neurology Society, called the decision “a missed opportunity.” “We’ve been waiting decades for a treatment that could slow Alzheimer’s,” she said. “While HAS’s concerns are valid, denying access entirely risks leaving patients with no options at all.” (SFN statement, June 2024)
Others, like Dr. Bruno Dubois of the Alzheimer’s Disease Research Center at Pitié-Salpêtrière, argue that the rejection could stifle innovation. “If France doesn’t reimburse, why would pharmaceutical companies invest in Alzheimer’s drugs?” he asked. “This disease affects millions, yet we’re still treating it as a niche market.”
HAS defended its stance, noting that reimbursement decisions are based on rigorous cost-benefit analysis. “Our role is to ensure that public funds are used where they provide the greatest benefit to the population,” said Dr. Dominique Le Guludec, HAS director. “Leqembi’s place in therapy is not yet clear, and we cannot justify its cost without stronger evidence.” (HAS press release, June 2024)
What Happens Next? The Road Ahead for Leqembi in France
The rejection is not the end of the story. Several developments could shift the landscape:
1. Appeals and Legal Challenges
Patient advocacy groups, including France Alzheimer and ICM, are considering legal action to overturn HAS’s decision. They argue that the authority failed to account for the psychological and economic burden of Alzheimer’s on families.
2. New Clinical Data
Results from ongoing trials, particularly the TRAILBLAZER-ALZ 3 extension study, could influence HAS’s position. If long-term data shows sustained benefits, the authority may revisit its decision in 2025.
3. EMA’s Decision on Leqembi
The European Medicines Agency (EMA) is expected to rule on Leqembi’s approval in late 2024. If approved, France may face pressure to reconsider reimbursement, especially if other EU countries (like Germany) adopt the drug.
4. Policy Reforms in France
Some lawmakers are pushing for reforms to France’s Alzheimer’s disease plan, including:
- Expanding access to diagnostic tools (e.g., amyloid PET scans).
- Creating a national registry for Alzheimer’s patients to track treatment outcomes.
- Negotiating lower drug prices through collective purchasing.
What You Can Do
If you or a loved one is affected by Alzheimer’s:
- Contact France Alzheimer for support and trial information.
- Check eligibility for clinical trials via ClinicalTrials.gov.
- Monitor updates from HAS and the ANSM.
- Share your story with policymakers to advocate for better access.
Your experience matters—join the conversation in the comments below or share this article to raise awareness.
FAQ: Common Questions About Leqembi and Alzheimer’s Treatment
Yes, but reimbursement varies:
- United Kingdom: Not yet approved by the NHS; under review by NICE.
- Germany: Not approved; EMA decision pending.
- Switzerland: Approved but not reimbursed by basic health insurance.
Yes, but with limited efficacy:
- Aduhelm (aducanumab): FDA-approved but controversial; not widely used due to safety concerns.
- Cholinesterase inhibitors (e.g., donepezil, rivastigmine): Slow symptoms but don’t alter disease progression.
- NMDA antagonists (e.g., memantine): Used for moderate-to-severe Alzheimer’s.
No other drug has shown the same potential for slowing early-stage decline as Leqembi.
Join or support organizations like:
Attend public hearings, write to policymakers, and participate in awareness campaigns.
Final Thoughts: A Setback, Not the End of the Story
France’s decision to reject Leqembi reimbursement is a blow to patients and neurologists who saw the drug as a beacon of hope. Yet, as with many medical breakthroughs, the journey is far from over. Clinical trials, legal challenges, and policy shifts could yet open doors for those in need.
For now, the message is clear: Alzheimer’s research demands urgency, and access to innovative treatments must be a priority. Whether through trials, private means, or future policy changes, the fight for better care continues.
What’s your experience with Alzheimer’s treatment? Share your thoughts in the comments—or spread the word to ensure no one faces this disease alone.
Related reading